NuLiv Science receives positive clinical study results on its 90-day toxicity study for AstraGin®

Share Article

Nuliv Science, a nutraceutical ingredient developer & research institute, announced today that it received clinical study results for its 90-Day Toxicity Study on its flagship ingredient, AstraGin®, a wellness & absorption enhancing ingredient. The positive toxicity study results confirm the continued commitment to safety of ingredients to stakeholders in the industry.

“We completed a 28 day sub-acute toxicity study but wanted to evaluate a longer time span. A 90 day study evaluating same dosage ranges confirmed that AstraGin® is safe for consumption,” said Richard Wang, General Manager of NuLiv Science

Nuliv Science, a nutraceutical ingredient developer & research institute, announced today that it received clinical study results for its 90-Day Toxicity Study on its flagship ingredient, AstraGin®, a wellness & absorption enhancing ingredient.

The study sponsored by NuLiv Science was carried out to evaluate the toxicity of AstraGin®, after 90 days repeated administration by oral route in Wistar rats, to evaluate the characterization of the test item toxicity, for an indication of the dose response relationship and the determination of the No-Observed Adverse Effect Level (NOAEL).

In keeping with best practices, the study was framed within the OECD Guideline for the Testing of Chemicals No. 408 “Repeated Dose 90-Day Oral Toxicity Study in Rodents”; adopted September 21, 1998.

“We completed a 28-day sub-acute toxicity study but wanted to evaluate a longer time span. A 90-day study evaluating same dosage ranges confirmed that AstraGin® is safe for consumption”, said Richard Wang, General Manager of NuLiv Science.

Based on observations and analysis in the study, it was concluded that Astragin® did not produce any significant changes in physical, physiological, neurobehavioral, biochemical, haematological and histopathological parameters in any of the doses used in the current study.

Furthermore, there were no treatment-related changes that were considered to be of toxicological significance. Results of the current study support the safety of AstraGin® in Wistar rats.

Wang commented, “We hope that additional safety studies will provide reassurance to end users, industry and government alike.”

___________________

About NuLiv Science:

NuLiv Science is a global leader in research & nutraceutical solutions. With its researched-back ingredient portfolio, the company offers a wide-range of natural ingredients offering benefits for: improved bioavailability & absorption, sports nutrition, weight management, glucose balance, bone health, cognitive performance & nootropics, lung health, and more. It’s branded ingredient line includes: AstraGin®, InnoSlim® , ActiGin® , Acteolin™ , OsteoSine™, RosaEx™, and many other time-tested natural ingredients for wellness.

For further information, please contact:
Richard Wang
General Manager
NuLiv Science
richardw(at)nulivusa(dot)com
T: (909) 594-3188

  • * *

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Josh Beaty
NuLiv Science
+1 (909) 594-3188
Email >